$475 million acquisition of Metrics Contract Services by Catalent Inc.
Catalent Inc. is set to acquire Metrics Contract Services in a USD $475 million bid to expand its high-potent capacities and oral development and manufacturing capabilities by the end of 2022
Drug and healthcare solutions provider Catalent Inc. have announced their plans to acquire full-service CDMO Metrics Contract Services to bolster its capabilities for integrated oral solid formulation development, manufacturing, and packaging.
The USD $475 million acquisition, which includes a facility in Greenville, North Carolina to join Catalent’s headquarters in Somerset, New Jersey, will also expand Catalent’s capacity in handling high-potent compounds. The Greenville facility expands over 333,000 square-feet and is designed with comprehensive acceleration and development capabilities for early drug development through to commercial launch programs. With over USD $100 million in improvements over the last 5 years and 16 manufacturing suites, 11 of which are designed to handle highly potent compounds, the facility's annual production capacity is estimated to exceed 1 billion oral solid dose units. Catalent hopes the acquisition will strengthen their efforts to meet customer expectations in simplifying and accelerating development and manufacturing programs.
Group President of Catalent’s Pharma & Consumer Health segment Aris Gennadios commented: “This acquisition will further expand Catalent’s ability to meet our customers’ expectations in fast-growing areas of the business and patient need. The experienced team and consistently improved, state-of-the-art facility in Greenville will provide Catalent’s customers with immediate, fit-for-scale capacity for in-demand highly potent drugs and other oral solid small-to-mid-size batch needs. This capacity is particularly important for customers with R&D pipelines featuring accelerated, orphan, and rare disease programs for oncology and other important therapeutic areas.”
Scott Richards, CEO of Mayne Pharma, added: “Over the past several years, Metrics has undergone a period of transformational change to expand its footprint and service offering, becoming a global end-to-end novel oral solid CDMO. Catalent, a global leader in advanced drug development and manufacturing, is well-positioned to continue to invest in and accelerate the growth of Metrics and we believe this transaction will be extremely positive for our Greenville team and customers.”
The acquisition is expected to be closed before the end of 2022, adding a team of over 400 employees to Catalent.
Source: Catalent to Acquire Metrics Contract Services for $475 Million
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...